Hope for rare fat disorder: new drug shows promise in Long-Term trial

NCT ID NCT06679270

Recruiting now Disease control Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study looks at the long-term safety and effectiveness of a daily injection called metreleptin for people with familial partial lipodystrophy, a rare condition where fat is distributed abnormally. About 24 participants who completed a previous study will receive the drug for an extended period. The goal is to monitor side effects and check if the drug helps control blood sugar and fat levels over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL PARTIAL LIPODYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial partial lipodystrophy partial lipodystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FAMILIAL PARTIAL LIPODYSTROPHY

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Flourish Research
RECRUITING

Boca Raton, Florida, 33434, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
The Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
University of Alabama
RECRUITING

Birmingham, Alabama, 35233, United States
University of Michigan
RECRUITING

Ann Arbour, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.